CANTOS trial of canakinumab demonstrates that inflammation is a lung cancer promoter
Cells need to accumulate multiple mutations in order to induce the 10 hallmarks of cancer:
Search Results for: CANTOS
How important is inflammation in breast cancer progression?
Not very, according to the REACT Study conducted by the Imperial College London. The study was predicated on the importance of COX-2 in driving inflammation that contributes to tumorigenesis. The thinking was that administering celecoxib (Celebrex), a COX-2 inhibitor, could reduce breast cancer progression, as suggested in smaller observational trials.